Non-Small Cell Lung Cancer: Lung-MAP Sub-Study

What is the Purpose of this Study?

The purpose of this study is to determine whether a combination of drugs (capmatinib, osimertinib, and ramucirumab) is beneficial compared to another combination (capmatinib and osimertinib) for treating non-small cell lung cancer tumors that have gene changes (EGFR and MET gene changes). Specifically, researchers want to learn whether the combination of 3 targeted drugs work together to lower the chance of lung cancer growing or spreading. Participants will receive either capmatinib and osimertinib, or capmatinib and osimertinib with ramucirumab. The drug combinations in both groups are experimental; this study is part of a larger research study that evaluates many treatments for advanced non-small cell lung cancer.


Eligibility

  • Patients must meet all SCREENING/PRE-SCREENING and SUB-STUDY REGISTRATION COMMON ELIGIBILITY CRITERIA as specified in S1400: Phase II/III Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
  • Participants must have been assigned to S1900G by the Southwest Oncology Group (SWOG) Statistics and Data Management Center (SDMC). Assignment to S1900G is determined by the LUNGMAP protocol
  • Participants must have documentation of NSCLC with a sensitizing EGFR mutation and have radiologically or clinically progressed (in the opinion of the treating physician) on osimertinib, alone or in combination with other agent(s), as their most recent line of therapy. Any number of prior lines of therapy is allowed
Show more

Where can I participate?

  • Cedars-Sinai Cancer at Beverly Hills (THO) : Garrett Crook
  • Cedars-Sinai Cancer at Hunt Cancer Center - TMPNCC (CSMC Affiliate)
  • Cedars-Sinai Cancer at SOCC : Garrett Crook


More about this Clinical Trial

What is the full name of this clinical trial?

S1900G: A Randomized Phase II Study of INC280 plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer

Study Details
Disease Type/Condition

Lung

Principal Investigator

Reckamp, Karen

Co-Investigators

Alain Mita, Andrew Horodner, David Chan, David Hoffman, Hugo Hool, Jeremy Lorber, Jessica Gunderson, Kamya Sankar, Kevin Scher, Ronald Natale, Swati Sikaria, Syed Jilani, Thomas Lowe, Vanessa Dickey

Age Group

Adult

Phase

II

IRB Number

STUDY00002914

ClinicalTrials.gov ID

NCT05642572

Key Eligibility
ClinicalTrials.gov

How do I learn more about this study?
Name

Garrett Crook

Phone
310-423-2133
Email
Garrett.Crook@cshs.org
Study Details
Disease Type/Condition

Lung

Principal Investigator

Reckamp, Karen

Age Group

Adult

Phase

II

IRB Number

S1900G

ClinicalTrials.gov ID

NCT05642572

Key Eligibility
ClinicalTrials.gov

Contact
Name

Garrett Crook

Phone
310-423-2133
Email
Garrett.Crook@cshs.org